

ARTICLE

Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems

Bradley J Gardiner

Infectious diseases physician¹

Andrew J Stewardson

Infectious diseases physician¹

Iain J Abbott

Infectious diseases physician and Clinical microbiologist^{1,2}

Anton Y Peleg

Director¹ and Research group leader³

¹ Department of Infectious Disease, Alfred Health and Central Clinical School, Monash University, Melbourne

² Department of Medical Microbiology and Infectious Diseases, Research and Development Unit, Erasmus Medical Centre, Rotterdam, The Netherlands

³ Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne

Keywords

antibiotic resistance, fosfomycin, nitrofurantoin, urinary tract infection

Aust Prescr 2019;42:14–9

<https://doi.org/10.18773/austprescr.2019.002>

SUMMARY

Uncomplicated urinary tract infection is one of the most common indications for antibiotic use in the community. However, the Gram-negative organisms that can cause the infection are becoming more resistant to antibiotics.

Many multidrug resistant organisms retain susceptibility to two old antibiotics, nitrofurantoin and fosfomycin. Advantages over newer drugs include their high urinary concentrations and minimal toxicity.

Fosfomycin is a potential treatment option for patients with uncomplicated urinary tract infection due to resistant organisms. Nitrofurantoin may be more effective and can be used for urinary infections in pregnant women.

Introduction

Antimicrobial resistance is increasing worldwide, resulting in infections that are more difficult to treat and associated with higher mortality, morbidity and cost.^{1–3} In Australia, multidrug resistant Gram-negative bacilli are responsible for a rising proportion of community-acquired uncomplicated urinary tract infections. Consequently, empiric therapy is more likely to fail. This has resulted in increasing numbers of patients with uncomplicated urinary tract infections requiring hospitalisation for intravenous antibiotics because there are no oral treatment options.

Limited Australian data are available for antimicrobial resistance rates in community-onset urinary tract infections.^{4,5} One large national survey of urinary isolates from 2015 found resistance rates in *Escherichia coli* of 43% for ampicillin, 9% for amoxicillin with clavulanic acid, 16% for cefazolin, 22% for trimethoprim, and 7% for ciprofloxacin.⁶ It is likely that resistance rates have continued to rise since then.

There are few new antibiotics on the horizon and those that have been recently approved are mostly for intravenous use, so older ‘forgotten’ drugs are being re-explored for the treatment of cystitis.^{7–10} Nitrofurantoin and fosfomycin are old antibiotics. They share some important properties including high concentrations in the urinary tract, a minimal impact on gastrointestinal flora and a low propensity for resistance (Table).

Nitrofurantoin

Nitrofurantoin has been available since 1953, and in Australia since the 1970s. Its exact mechanism of action is not well understood and presumably multifactorial. Nitrofurantoin requires reduction by bacterial enzymes producing ‘highly reactive electrophilic’ metabolites. These then inhibit protein synthesis by interfering with bacterial ribosomal proteins.¹¹

Nitrofurantoin has 80% oral bioavailability, and approximately 25% is excreted unchanged in the urine, with only a small portion reaching the colon.¹² Like fosfomycin, therapeutic concentrations are only reached in the urinary tract,¹³ so the clinical use of nitrofurantoin is limited to the treatment of uncomplicated urinary tract infection in women. Administration with food results in higher urinary concentrations and fewer gastrointestinal adverse effects.

Antimicrobial activity

Nitrofurantoin is active against common causes of urinary tract infection including *E. coli*, *Citrobacter* and *Enterococcus*. *Klebsiella* and *Enterobacter* are less reliably susceptible. *Serratia*, *Acinetobacter*, *Morganella*, *Proteus* and *Pseudomonas* are usually resistant.¹⁴ Overall, resistance to nitrofurantoin is uncommon and many multidrug resistant organisms retain susceptibility.^{15–17} Australian data are limited, but studies suggest resistance rates in *E. coli* of 1–2%.^{4,6}

Table Features of nitrofurantoin and fosfomycin

Characteristic	Nitrofurantoin	Fosfomycin
Year of discovery	1953	1969
Formulations	Nitrofurantoin macrocrystal 50 mg, 100 mg capsules Slow-release formulation not available in Australia Older microcrystal formulation less available now (more adverse effects)	Fosfomycin trometamol 3 g sachet containing granules to be dissolved in water Intravenous formulation available but for specialised use only
Pharmacokinetics	High urinary concentrations Serum concentrations negligible	Long half-life with high urinary concentrations Serum concentrations inadequate for treatment of systemic infection
Mechanism of action	Not well understood, multifactorial, inhibits ribosomal protein synthesis	Inhibits pyruvyl transferase and therefore cell wall synthesis
Spectrum of activity	Mostly susceptible: <i>E. coli</i> , <i>Enterococcus</i> Variably susceptible: <i>Klebsiella</i> , <i>Enterobacter</i> , <i>Citrobacter</i> and <i>Providencia</i> Typically resistant: <i>Proteus</i> , <i>Serratia</i> , <i>Acinetobacter</i> , <i>Morganella</i> and <i>Pseudomonas</i>	Mostly susceptible: <i>E. coli</i> Variably susceptible: <i>Klebsiella</i> , <i>Proteus</i> , <i>Citrobacter</i> , <i>Enterobacter</i> , <i>Pseudomonas</i> and <i>Enterococcus</i> Typically resistant: <i>Morganella</i> and <i>Acinetobacter</i>
Resistance	Uncommon	Uncommon
Indications	Uncomplicated urinary tract infection in women	Uncomplicated urinary tract infection in women
Dosing	50–100 mg 4 times a day for 5 days	Single 3 g oral dose
Adverse events	Infrequent, mainly gastrointestinal Rare reports of pulmonary or liver toxicity, peripheral neuropathy	Infrequent, mainly gastrointestinal (9% diarrhoea, 4% nausea)
Pregnancy and breastfeeding	Category A, although not recommended beyond 38 weeks gestation due to risk of haemolytic anaemia in neonates. For this reason it is also best to avoid during the first month of breastfeeding	Category B2, small amounts excreted in breast milk so not recommended in breastfeeding
Children	Avoid <1 month of age	Avoid <12 years of age
Interactions	Few significant drug interactions	Co-administration with metoclopramide can lower serum and urine concentrations
Renal impairment	Contraindicated if CrCl <30 mL/min Cautious use between CrCl 30–60 mL/min if benefits outweigh risks	Dose reduction required if CrCl <50 mL/min

CrCl creatinine clearance

Efficacy and safety

A meta-analysis of 27 older controlled trials (4807 patients) found clinical cure rates of 79–92%, similar to comparator antibiotics. Only mild toxicities (most commonly gastrointestinal) and no cases of pulmonary fibrosis or hepatotoxicity were reported.¹⁸ Dosing recommendations for the standard formulation are 50–100 mg four times daily. There is a long-acting formulation available overseas, but not in Australia, which can be dosed twice daily. This slow-release formulation (100 mg three times daily) was used in a recent open-label comparison with fosfomycin. The cure rate was 70% in the nitrofurantoin group.¹⁹

Historically nitrofurantoin was thought to be contraindicated if the creatinine clearance was less than 60 mL/minute due to an increased risk of toxicity. However, recommendations have been changing to allow cautious, short-term use in patients with mild renal impairment (30–60 mL/min) if there are no alternative antibiotics.^{20,21} Nitrofurantoin can be used to treat cystitis in pregnancy (although not beyond 38 weeks gestation due to the risk of haemolytic anaemia in the neonate).

Nitrofurantoin became a preferred drug in the international consensus guidelines for urinary tract infection in 2010.²² These emphasised the lower rates of ‘collateral damage’ on gastrointestinal flora.²³⁻²⁴

It remains to be seen if resistance rates increase as a consequence of this recommendation and the subsequent rise in nitrofurantoin prescribing. The true incidence of major hepatic and pulmonary toxicity is unclear, but this appears to be more common with long-term use in the elderly.¹⁴ For the short-term treatment of uncomplicated urinary tract infection in otherwise healthy young women, nitrofurantoin is a safe and effective choice, and overall efficacy and rates of adverse events appear similar to comparator antibiotics. In patients with infections due to multidrug resistant organisms and therefore few alternative treatment options, we recommend using 100 mg four times daily for five days, administered with food to optimise absorption and efficacy.

Fosfomycin

Fosfomycin was first isolated in Spain in 1969, and was introduced in Europe throughout the 1970s.²⁵ It is a small molecule from a unique drug class that acts by inhibiting pyruvyl transferase. This enzyme is responsible for synthesising the precursors of peptidoglycan, the key component of the bacterial cell wall. Uptake in the USA was initially limited due to problems with susceptibility testing, but this was standardised in 1983.

Fosfomycin trometamol, an oral formulation that can be taken as a single 3 g dose, was introduced in 1995. In many countries it is now a first-line treatment option for uncomplicated urinary tract infection in women.²² This single-dose regimen is attractive due to better adherence and is generally well tolerated. While transient gastrointestinal disturbance can occur, serious adverse events are rare.²⁶

In Australia, fosfomycin was only previously available via the Special Access Scheme. The Therapeutic Goods Administration has now approved it for acute uncomplicated lower urinary tract infection, in females more than 12 years of age, caused by susceptible organisms (Enterobacteriaceae including *E. coli*, and *Enterococcus faecalis*).

Antimicrobial activity

Susceptibility testing for fosfomycin is available, but can be complicated and is not necessarily routine in Australian microbiology laboratories. Fosfomycin is most active against *E. coli*, and minimum inhibitory concentrations are typically low.²⁷⁻²⁹ Other urinary pathogens such as *Klebsiella*, *Proteus*, *Citrobacter*, *Enterobacter*, *Pseudomonas* and *Enterococcus* have variable susceptibility.³⁰⁻³² *Morganella morganii* and *Acinetobacter* are typically resistant.²⁸ Urinary concentrations following a single 3 g dose are generally sufficient to treat patients infected with

susceptible organisms, although some recent data suggest more variability in urinary concentrations than previously thought.^{33,34}

As fosfomycin has a unique structure there is minimal cross-resistance with other antibiotics. At present, many multidrug resistant isolates remain susceptible to fosfomycin, even in geographic regions where there has been widespread use of the drug.^{35,36}

No comprehensive studies examining fosfomycin susceptibility have been conducted in Australia.

While resistant subpopulations of bacteria may develop with fosfomycin exposure, resistant strains do not seem to easily survive in vivo.^{32,37-40} However, there are multiple resistance mechanisms and there are reports of increasing resistance correlating with higher fosfomycin usage in Spain.^{32,41-43} Plasmid-mediated resistance, which could disseminate more readily, has been described in Japan,⁴⁴ and among livestock⁴⁵ and pets⁴⁶ in China.

Efficacy and safety

Historically, the clinical efficacy of fosfomycin was thought to be similar to antibiotics such as trimethoprim, trimethoprim/sulfamethoxazole, fluoroquinolones, beta-lactams and nitrofurantoin, with reported cure rates of 75–90%.⁴⁷⁻⁵¹ However, methodological flaws in the older studies may have resulted in clinical efficacy being overestimated.

A recent large randomised trial found a lower clinical cure rate with fosfomycin compared with nitrofurantoin (58% vs 70%, $p=0.004$).¹⁹ While some recent observational studies have demonstrated fosfomycin efficacy in uncomplicated urinary tract infection caused by resistant organisms,⁵²⁻⁵⁶ including non-inferiority to carbapenems,^{57,58} there are reports of treatment failures particularly with *Klebsiella*.⁵⁹

As low serum concentrations lead to treatment failures, fosfomycin is not appropriate for patients with bacteraemia or upper urinary tract infections such as pyelonephritis. Occasionally, longer courses have been used to treat complicated urinary tract infection, for example as completion therapy when there are no oral alternatives to intravenous antibiotics.⁵⁷ There is also an emerging role in prostatitis and perioperative prophylaxis for urological procedures in men.⁶⁰⁻⁶² Specialist infectious diseases input should be sought for these complex cases if off-label use or prolonged courses of therapy are being considered.

Fosfomycin is generally well tolerated, with adverse events rare and usually transient. Gastrointestinal events (9% diarrhoea, 4% nausea) have been most commonly reported with rare reports of other more serious problems.²⁶ Co-administration with metoclopramide can lower serum and urinary concentrations and should be avoided, but there are few other problematic drug

interactions. Fosfomycin is classified in pregnancy category B2. It is not recommended in breastfeeding as small amounts are excreted in breast milk. Given there are minimal data on use in children under 12 years of age, it is not advised for this group.

In Australia, we currently recommend reserving fosfomycin for the treatment of uncomplicated urinary tract infection in patients when the standard first-line drugs are not an option. Part of the rationale behind this is to minimise the emergence of resistance and prolong the usefulness of fosfomycin for patients without alternative options.³⁵ As resistance to other drugs inevitably rises and local experience increases, fosfomycin may become a first-line option in the future.

Antibiotic resistance

While re-exploring older 'forgotten' drugs like nitrofurantoin and fosfomycin is a useful strategy, it represents only part of the multifaceted response required to tackle the complex problem of antimicrobial resistance and 'preserve the miracle' of antimicrobials over the coming decades.⁶³ As we have seen historically with virtually all other antibiotics, resistance is likely to emerge as usage increases. It remains to be seen how long this will take, to what extent it will occur and whether it will be via dissemination of existing resistance mechanisms or evolution of new ones. The increasing failure of standard empirical therapy for urinary tract infection is foreseeable, and it is likely that more patients will require microbiological testing before starting antibiotics, not only for individualised patient management but also for broader epidemiological surveillance to inform guideline recommendations.

Consultation with an infectious diseases specialist can assist with the management of patients with multidrug resistant infections and leads to better outcomes.⁶⁴ Other important strategies include the development of new antimicrobial drugs, preserving those currently available by judicious use, implementation of comprehensive antimicrobial stewardship programs and stringent infection control practices worldwide to reduce the spread of resistant organisms.

Conclusion

Nitrofurantoin is suitable for uncomplicated lower urinary tract infections. Bacterial resistance is uncommon.

Fosfomycin is a safe and effective antibacterial drug for urinary tract infections, but its use should be limited to delay the development of resistance. It will prove to be a useful treatment option for community-based treatment of patients with resistant organisms. ◀

Bradley Gardiner and Iain Abbott are supported by Australian Government National Health and Medical Research Council (NHMRC) Research Training Program Scholarships (APP1150351 and APP1114690). Andrew Stewardson is supported by an NHMRC Fellowship (APP1141398). Anton Peleg is part funded through an NHMRC Practitioner Fellowship (APP1117940) and is the recipient of an investigator-initiated research grant from Merck, Sharp & Dohme.

REFERENCES

- Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. *Clin Infect Dis* 2016;63:960-5. <https://doi.org/10.1093/cid/ciw396>
- Prakash V, Lewis JS 2nd, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β -lactamases. *Antimicrob Agents Chemother* 2009;53:1278-80. <https://doi.org/10.1128/AAC.01519-08>
- Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al.; Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46:155-64. <https://doi.org/10.1086/524891>
- Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Pearson JC, Bell JM; Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010. *Commun Dis Intell Q Rep* 2013;37:E219-23.
- Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Daly DA, Bell JM; Australian Group on Antimicrobial Resistance. Enterobacteriaceae Sepsis Outcome Programme annual report, 2013. *Commun Dis Intell Q Rep* 2014;38:E327-33.
- Australian Commission on Safety and Quality in Health Care. AURA 2017: second Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2017. <https://www.safetyandquality.gov.au/publications/second-australian-report-on-antimicrobial-use-and-resistance-in-human-health> [cited 2019 Jan 3]
- Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics. Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. *Int J Antimicrob Agents* 2017;49:98-101. <https://doi.org/10.1016/j.ijantimicag.2016.09.029>
- Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, et al.; Infectious Diseases Society of America. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. *Clin Infect Dis* 2013;56:1685-94. <https://doi.org/10.1093/cid/cit152>
- Gardiner BJ, Golan Y. Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections. *Expert Rev Anti Infect Ther* 2016;14:451-63. <https://doi.org/10.1586/14787210.2016.1173542>
- Maseda E, Aguilar L, Gimenez MJ, Gilsanz F. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. *Expert Rev Anti Infect Ther* 2014;12:1311-24. <https://doi.org/10.1586/14787210.2014.950230>

11. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. *J Antimicrob Chemother* 1994;33 Suppl A:23-30. https://doi.org/10.1093/jac/33.suppl_A.23
12. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. *Med Clin North Am* 2006;90:1089-107. <https://doi.org/10.1016/j.mcna.2006.07.006>
13. Cunha BA. Nitrofurantoin--current concepts. *Urology* 1988;32:67-71. [https://doi.org/10.1016/0090-4295\(88\)90460-8](https://doi.org/10.1016/0090-4295(88)90460-8)
14. Grayson ML, Cosgrove SE, Crowe SM, Hope W, Mccarthy JS, Mills J, et al., editors. *Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs*. 7th ed. Boca Raton (FL): CRC Press; 2017.
15. Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J. Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. *Antimicrob Agents Chemother* 2016;60:2680-3. <https://doi.org/10.1128/AAC.02897-15>
16. Sanchez GV, Baird AM, Karlowsky JA, Master RN, Bordon JM. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary *Escherichia coli* from US outpatients. *J Antimicrob Chemother* 2014;69:3259-62. <https://doi.org/10.1093/jac/dku282>
17. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI. Nitrofurantoin resistance mechanism and fitness cost in *Escherichia coli*. *J Antimicrob Chemother* 2008;62:495-503. <https://doi.org/10.1093/jac/dkn222>
18. Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. *J Antimicrob Chemother* 2015;70:2456-64. <https://doi.org/10.1093/jac/dkv147>
19. Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. *JAMA* 2018;319:1781-9. <https://doi.org/10.1001/jama.2018.3627>
20. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2015;63:2227-46. <https://doi.org/10.1111/jgs.13702>
21. Singh N, Gandhi S, McArthur E, Moist L, Jain AK, Liu AR, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. *CMAJ* 2015;187:648-56. <https://doi.org/10.1503/cmaj.150067>
22. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011;52:e103-20. <https://doi.org/10.1093/cid/ciq257>
23. Stewardson AJ, Vervoort J, Adriaenssens N, Coenen S, Godycki-Cwirko M, Kowalczyk A, et al.; SATURN WPI Study Group; SATURN WP3 Study Group. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study. *Clin Microbiol Infect* 2018;24:972-9. <https://doi.org/10.1016/j.cmi.2017.12.026>
24. Stewardson AJ, Gaia N, Francois P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. *Clin Microbiol Infect* 2015;21:344 e1-11. <https://doi.org/10.1016/j.cmi.2014.11.016>
25. Hendlin D, Stapley EO, Jackson M, Wallick H, Miller AK, Wolf FJ, et al. Phosphonomycin, a new antibiotic produced by strains of streptomycetes. *Science* 1969;166:122-3. <https://doi.org/10.1126/science.166.3901.122>
26. Iarikov D, Wassel R, Farley J, Nambiar S. Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA adverse event reporting system database. *Infect Dis Ther* 2015;4:433-58. <https://doi.org/10.1007/s40121-015-0092-8>
27. Seitz M, Stief C, Waidelich R. Local epidemiology and resistance profiles in acute uncomplicated cystitis (AUC) in women: a prospective cohort study in an urban urological ambulatory setting. *BMC Infect Dis* 2017;17:685. <https://doi.org/10.1186/s12879-017-2789-7>
28. Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. *Int Urol Nephrol* 2015;47:1059-66. <https://doi.org/10.1007/s11255-015-1018-9>
29. Rossignol L, Vaux S, Maugat S, Blake A, Barlier R, Heym B, et al. Incidence of urinary tract infections and antibiotic resistance in the outpatient setting: a cross-sectional study. *Infection* 2017;45:33-40. <https://doi.org/10.1007/s15010-016-0910-2>
30. Raz R. Fosfomycin: an old--new antibiotic. *Clin Microbiol Infect* 2012;18:4-7. <https://doi.org/10.1111/j.1469-0691.2011.03636.x>
31. Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I. Fosfomycin and comparator activity against select Enterobacteriaceae, *Pseudomonas*, and *Enterococcus* urinary tract infection isolates from the United States in 2012. *Infect Dis Ther* 2017;6:233-43. <https://doi.org/10.1007/s40121-017-0150-5>
32. Sherry N, Howden B. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications. *Expert Rev Anti Infect Ther* 2018;16:289-306. <https://doi.org/10.1080/14787210.2018.1453807>
33. Wijma RA, Koch BC, van Gelder T, Mouton JW. High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers. *Clin Microbiol Infect* 2018;24:528-32. <https://doi.org/10.1016/j.cmi.2017.08.023>
34. Abbott IJ, Meletiadiis J, Belghanch I, Wijma RA, Kanioura L, Roberts JA, et al. Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an *in vitro* dynamic bladder infection model. *J Antimicrob Chemother* 2018;73:709-19. <https://doi.org/10.1093/jac/dkx441>
35. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, et al. *In vitro* activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. *Antimicrob Agents Chemother* 2015;59:7842-6. <https://doi.org/10.1128/AAC.02019-15>
36. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. *Int J Antimicrob Agents* 2010;35:240-3. <https://doi.org/10.1016/j.ijantimicag.2009.10.019>
37. Martín-Gutiérrez G, Docobo-Pérez F, Rodríguez-Beltrán J, Rodríguez-Martínez JM, Aznar J, Pascual A, et al. Urinary tract conditions affect fosfomycin activity against *Escherichia coli* strains harboring chromosomal mutations involved in fosfomycin uptake. *Antimicrob Agents Chemother* 2017;62:e01899-17. <https://doi.org/10.1128/AAC.01899-17>
38. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. *In vitro* activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. *Int J Antimicrob Agents* 2003;22 Suppl 2:53-9. [https://doi.org/10.1016/S0924-8579\(03\)00230-9](https://doi.org/10.1016/S0924-8579(03)00230-9)
39. Nilsson AI, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 2003;47:2850-8. <https://doi.org/10.1128/AAC.47.9.2850-2858.2003>
40. Karageorgopoulos DE, Wang R, Yu XH, Falagas ME. Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. *J Antimicrob Chemother* 2012;67:255-68. <https://doi.org/10.1093/jac/dkr466>
41. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernández S, et al.; Spanish ESBL-EARS-Net Study Group. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli*. *J Antimicrob Chemother* 2010;65:2459-63. <https://doi.org/10.1093/jac/dkq346>

42. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. *Am J Infect Control* 2014;42:1033-8. <https://doi.org/10.1016/j.ajic.2014.06.013>
43. Rodríguez-Avial C, Rodríguez-Avial I, Hernández E, Picazo JJ. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing *Escherichia coli* urinary isolates (2005-2009-2011)]. *Rev Esp Quimioter* 2013;26:43-6.
44. Wachino J, Yamane K, Suzuki S, Kimura K, Arakawa Y. Prevalence of fosfomycin resistance among CTX-M-producing *Escherichia coli* clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. *Antimicrob Agents Chemother* 2010;54:3061-4. <https://doi.org/10.1128/AAC.01834-09>
45. Ho PL, Chan J, Lo WU, Law PY, Li Z, Lai EL, et al. Dissemination of plasmid-mediated fosfomycin resistance *fosA3* among multidrug-resistant *Escherichia coli* from livestock and other animals. *J Appl Microbiol* 2013;114:695-702. <https://doi.org/10.1111/jam.12099>
46. Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z, et al. Dissemination of the fosfomycin resistance gene *fosA3* with CTX-M β -lactamase genes and *rmtB* carried on IncFII plasmids among *Escherichia coli* isolates from pets in China. *Antimicrob Agents Chemother* 2012;56:2135-8. <https://doi.org/10.1128/AAC.05104-11>
47. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. *Clin Ther* 1999;21:1864-72. [https://doi.org/10.1016/S0149-2918\(00\)86734-X](https://doi.org/10.1016/S0149-2918(00)86734-X)
48. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. *Int J Antimicrob Agents* 1998;10:39-47. [https://doi.org/10.1016/S0924-8579\(98\)00021-1](https://doi.org/10.1016/S0924-8579(98)00021-1)
49. Fosfomycin for urinary tract infections. *Med Lett Drugs Ther* 1997;39:66-8.
50. Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD. Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women. *Pharm World Sci* 1993;15:257-62. <https://doi.org/10.1007/BF01871127>
51. Falagas ME, Vouloumanou EK, Togiag AG, Karadima M, Kapaskelis AM, Rafailidis PI, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2010;65:1862-77. <https://doi.org/10.1093/jac/dkq237>
52. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. *Antimicrob Agents Chemother* 2012;56:5744-8. <https://doi.org/10.1128/AAC.00402-12>
53. Seroy JT, Grim SA, Reid GE, Wellington T, Clark NM. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. *J Antimicrob Chemother* 2016;71:2563-8. <https://doi.org/10.1093/jac/dkw178>
54. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. *Int J Antimicrob Agents* 2009;34:111-20. <https://doi.org/10.1016/j.ijantimicag.2009.03.009>
55. Rodríguez-Baño J, Alcalá JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. *Arch Intern Med* 2008;168:1897-902. <https://doi.org/10.1001/archinte.168.17.1897>
56. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections. *Int J Antimicrob Agents* 2007;29:62-5. <https://doi.org/10.1016/j.ijantimicag.2006.08.039>
57. Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β -lactamase urinary tract infections. *Int J Antimicrob Agents* 2016;48:56-60. <https://doi.org/10.1016/j.ijantimicag.2016.04.014>
58. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing *Escherichia coli*-related complicated lower urinary tract infection. *J Chemother* 2010;22:355-7. <https://doi.org/10.1179/joc.2010.22.5.355>
59. Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. *BMC Infect Dis* 2016;16:556. <https://doi.org/10.1186/s12879-016-1888-1>
60. Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? *Clin Infect Dis* 2014;58:e101-5. <https://doi.org/10.1093/cid/cit704>
61. Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, et al. Fosfomycin for treatment of prostatitis: new tricks for old dogs. *Clin Infect Dis* 2015;61:1141-3. <https://doi.org/10.1093/cid/civ436>
62. Rhodes NJ, Gardiner BJ, Neely MN, Grayson ML, Ellis AG, Lawrentschuk N, et al. Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. *J Antimicrob Chemother* 2015;70:2068-73. <https://doi.org/10.1093/jac/dkv067>
63. Spellberg B, Blaser M, Guidos RJ, Boucher HW, Bradley JS, Eisenstein BI, et al.; Infectious Diseases Society of America (IDSA). Combating antimicrobial resistance: policy recommendations to save lives. *Clin Infect Dis* 2011;52 Suppl 5:S397-428. <https://doi.org/10.1093/cid/cir153>
64. Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH. Infectious diseases consultation reduces 30-day and 1-year all-cause mortality for multidrug-resistant organism infections. *Open Forum Infect Dis* 2018;5:ofy026. <https://doi.org/10.1093/ofid/ofy026>